David Kabakoff, Ph.D.   |   Chairman

David Kabakoff, Ph.D. has served as Chair of our board of directors since December 2015. Dr. Kabakoff has served as Executive Partner at Sofinnova Investments, Inc. since May 2007 and became a founding Partner of HealthQuest Capital in 2012. Dr. Kabakoff presently sits on the board of several privately held life sciences companies, including RareCyte and Antiva Biosciences, Inc. He has previously served as a director of several other publicly traded and privately held life sciences companies, including publicly traded Castle Biosciences, Inc. from September 2017 to August 2021, Principia Biopharma, Inc. from June 2016 until August 2018 in advance of Principia’s September 2018 initial public offering, publicly traded lnterMune, Inc. from November 2005 to September 2014 and Amplimmune. In 2001, Dr. Kabakoff co-founded Salmedix, Inc., a company that developed cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer and led its acquisition in June 2005 by Cephalon, Inc. Previously, Dr. Kabakoff held the positions of Executive Vice President of Dura Pharmaceuticals, Inc. and President and Chief Executive Officer of Spiros, both pharmaceutical companies, Chief Executive Officer of Corvas International, Inc., a developer of biotherapeutics, and held senior executive positions with Hybritech, a biotechnology company. Dr. Kabakoff received a B.A. in chemistry from Case Western Reserve University and a Ph.D. in chemistry from Yale University.

• David Kabakoff, Ph.D. Chairman • Michael Richman Director • Elaine V. Jones, Ph.D. Director • John G. Houston, Ph.D. Director • Stephen Webster Director • Ellen G. Feigal, M.D. Director • Anne Borgman, M.D. Director